Navigation Links
HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
Date:3/26/2008

-Agreement provides Lilly researchers broad access to HistoRx AQUA(R)

technology for tissue biomarker analysis-

NEW HAVEN, Conn., March 26 /PRNewswire/ -- HistoRx, Inc. announced today that it has signed a three-year agreement with Eli Lilly and Company (NYSE: LLY) to make the HistoRx AQUA(R) technology for tissue biomarker analysis widely available to Lilly researchers and clinicians involved in drug discovery, preclinical research, and clinical development. The agreement extends and significantly expands the scope of the collaboration established by HistoRx and Lilly in 2005 to apply the HistoRx AQUA(R) technology to help advance select Lilly pharmaceutical development programs. Under the new agreement, HistoRx will provide Lilly researchers broad access to the AQUA(R) technology for tissue biomarker analysis, and HistoRx will develop customized AQUA(R) analysis-based immunohistochemical assays for use in Lilly drug discovery and development projects. HistoRx has the option to commercialize the assays and reagents developed during the course of the partnership for clinical use as predictive diagnostics.

HistoRx provides pharmaceutical and biotechnology companies access to AQUA(R) technology through partnership agreements by which HistoRx works with the company in applying its hallmark quantitative, multiparametric, tissue- based biomarker measurement and analysis to drug development programs, virtually eliminating the subjective interpretation inherent in conventional immunohistochemical methods. In the course of the partnership, HistoRx develops AQUA(R) analysis-based diagnostic assays that are linked to its partners' drugs in development. HistoRx may then commercialize these assays as prognostic tests or
'/>"/>

SOURCE HistoRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lilly Announces Termination of AIR Insulin Program
2. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
3. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
6. Lilly Declares Fourth-Quarter Dividend
7. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
8. Neptune Technologies expands into medicinal markets in Asia Pacific
9. CMPMedica Expands SearchMedica.com with Multiple Additional Vertical Search Applications co-developed with Convera(R)
10. Nova Biosource Fuels Expands Senior Executive Team
11. FDA Clears Expanded Use of Xofts Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2012)... 2012 Reportlinker.com announces that ... available in its catalogue: , ... http://www.reportlinker.com/p090668/Global-Biotechnology-Instrumentation-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_ This ... Biotechnology Instrumentation in US$ Million by ... Protein/Peptide Synthesizers, DNA Sequencers, Protein/Peptide Sequencers, ...
(Date:5/16/2012)... WOONSOCKET, R.I., May 16, 2012  MultiCell ... MCET ) is pleased to announce representatives ... findings for MCT-465 and MCT-485 at CIMT ... dedicated to cancer immunotherapy research and development.  ... 23-25 in Mainz, Germany.  The title of ...
(Date:5/15/2012)... Vermillion, Inc. (NASDAQ: VRML ), ... results for the first quarter ended March 31, 2012. ... In Q1, the volume of OVA1®, the company,s flagship ... ovarian masses, was generally in line with the forecast ... increase of 28% to 3,952 from the same year-ago ...
(Date:5/15/2012)... -- Cardium Therapeutics (NYSE Amex: CXM ... first quarter ended March 31, 2012, and other ... In addition to the announcement ... its goals for 2012, which were outlined in ... advance commercialization of its new Excellagen® advanced, physician-use ...
Breaking Biology Technology:Global Biotechnology Instrumentation Industry 2Global Biotechnology Instrumentation Industry 3Global Biotechnology Instrumentation Industry 4Global Biotechnology Instrumentation Industry 5Global Biotechnology Instrumentation Industry 6Global Biotechnology Instrumentation Industry 7Global Biotechnology Instrumentation Industry 8Global Biotechnology Instrumentation Industry 9Global Biotechnology Instrumentation Industry 10Global Biotechnology Instrumentation Industry 11Global Biotechnology Instrumentation Industry 12Global Biotechnology Instrumentation Industry 13Global Biotechnology Instrumentation Industry 14Global Biotechnology Instrumentation Industry 15Global Biotechnology Instrumentation Industry 16Global Biotechnology Instrumentation Industry 17Global Biotechnology Instrumentation Industry 18Global Biotechnology Instrumentation Industry 19Global Biotechnology Instrumentation Industry 20MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 2MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 3MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 4MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models 5Vermillion Reports First Quarter 2012 Results 2Vermillion Reports First Quarter 2012 Results 3Vermillion Reports First Quarter 2012 Results 4Vermillion Reports First Quarter 2012 Results 5Vermillion Reports First Quarter 2012 Results 6Vermillion Reports First Quarter 2012 Results 7Vermillion Reports First Quarter 2012 Results 8Cardium Presents First Quarter 2012 Financial Results and Recent Developments 2Cardium Presents First Quarter 2012 Financial Results and Recent Developments 3Cardium Presents First Quarter 2012 Financial Results and Recent Developments 4Cardium Presents First Quarter 2012 Financial Results and Recent Developments 5Cardium Presents First Quarter 2012 Financial Results and Recent Developments 6
... Neurological Function Now Available in the US, ... a new product called NeuroAid10(TM) in the US ... from,NeuroAid(TM) and is a combination of ten all-natural ... together the best of Asian,and Western medicine., ...
... Calif., March 6 Senetek PLC (OTC,Bulletin Board: ... development,of technologies that target the science of healthy ... two Veteran Sales and Marketing Executives,and the appointment ... Campagnoli joined the Company in December and has ...
... Inc., a,biodefense company specializing in the development and ... announced,today that it has completed the initial pharmacokinetic ... nerve agent prophylaxis., The PK studies were ... final,pegylated version of rBChE for the first time. ...
Other Biology Technology:Moleac Launches NeuroAid10(TM) in the United States 2Moleac Launches NeuroAid10(TM) in the United States 3Senetek PLC Announces Appointments of Key Personnel 2Senetek PLC Announces Appointments of Key Personnel 3PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 2PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 3PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008 4
(Date:5/21/2012)... US scientists has found there has been a massive ... off the coast of Antarctica.,Comparing detailed measurements taken during ... voyage to historical data dating back to 1970, scientists ... per cent reduction in the volume of Antarctic Bottom ... currents. , In an intensive and arduous 25-day observing ...
(Date:5/20/2012)... ARLINGTON, VA (May 14, 2012) - ... groundbreaking research being unveiled at the American Association ... The conference takes place Monday, May 21 - ... Hotel and Marina. Other topics to be discussed ... and tech transfer strategies, applications of multi-scale systems ...
(Date:5/20/2012)... uses a trial-and-error process to mimic the song of its ... times a day, making subtle changes in the pitch of ... process begins around the age of 40 days and is ... and ready to use his song to woo females. , ... process large quantities of information about its performance and use ...
Breaking Biology News(10 mins):Latest Southern Ocean research shows continuing deep ocean change 2Latest Southern Ocean research shows continuing deep ocean change 3AAPS National Biotechnology Conference to highlight innovative vaccines 2Songbirds' learning hub in brain offers insight into motor control 2Songbirds' learning hub in brain offers insight into motor control 3Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference 11873 1Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference 11873 2iGPS Announces iGPS bios u2122 a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries 11869 1iGPS Announces iGPS bios u2122 a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries 11869 2iGPS Announces iGPS bios u2122 a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries 11869 3Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 15966 1Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 15966 2Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 15966 3
... research in an animal model suggests that a diet ... variety of processed foods including meats, cheeses, beverages, and ... and may even contribute to the development of those ... study also suggests that dietary regulation of inorganic phosphates ...
... 12 WCC Smart Search & Match,the leading ... that Rudie Lion has joined the company as ... brings more than 15 years of product and ... market introduction efforts,for many high-tech products and solutions ...
... can halt the might of a tsunami are false and ... There are many reasons for preserving the world,s dwindling stocks ... of them, they say. , On the eve ... which claimed nearly a quarter of a million lives around ...
Other Biology News:Common food additive found to increase risk and speed spread of lung cancer 2Common food additive found to increase risk and speed spread of lung cancer 3Trees won't stop tsunamis, scientists warn 2Trees won't stop tsunamis, scientists warn 3
... The Tetrad 2 thermal cycler is a ... original Tetrad chassis, and it accepts the ... It delivers the same precision in thermal ... original Tetrad thermal cyclers, allowing easy transport ...
... The new Pierce ready-to-use 2-D gel marker ... analyst. This 2-D gel marker mix contains a ... offer important features of value to those who ... estimate pI and molecular weight values of proteins ...
... Tetrad thermal cycler expands the envelope ... DNA Engine cycler. It ... a footprint only twice the size, ... that run massive quantities of reactions, ...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
Biology Products: